Columbia Data Analytics is proud to share the highlights of our productive 2024! Check out our latest work in obesity, NASH, oncology and more.
2024 Peer-Reviewed Journal Articles
Baser O, Samayoa G, Yapar N, Baser E. Artificial intelligence in identifying patients with undiagnosed nonalcoholic steatohepatitis. J Health Econ Outcomes Res. 2024;11(2):86-94.
Baser O, Isenman L, Baser E, Li W, Cigdem B. Neighborhood socioeconomic status and postpartum depression among commercial health insurance enrollees: A retrospective cohort study. BMC Pregnancy Childbirth. 2024;732(24)
Baser O, Samayoa G, Dwivedi A, AlSaleh S, Cigdem B, Kizilkaya E. Cardiovascular events among patients with prostate cancer treated with abiraterone and enzalutamide. Acta Oncologica. 2024;63:137–146.
Baser O, Isenman L, Baser S, Samayoa G. Impact of semaglutide on osteoarthritis risk in patients with obesity: A retrospective cohort study. Obes Sci Pract. 2024;e762.
Baser O, Samayoa G, Rodchenko K, Isenman L, Baser E, Yapar N. The association between weight loss medications and cardiovascular complications. Obesity. 2024;32(7):1401-1409.
Baser O, Rodchenko K, Vivier E, Baser I, Lu Y. The impact of newly approved anti-obesity medications on osteoarthritis. Expert Opin Pharmacother. 2024; online ahead of print.
Baser O, Mohamed M, Samayoa G, Sarioglu S. Semaglutide and tirzepatide use and reduction of cardiovascular risks in adults with overweight and obesity. Med Res Arch. 2024;(12)8. https://doi.org/10.18103/mra.v12i8.0000.
Baser O, Alsaleh S, Zeng Y, Baser I. Behind the sadness of teen girls: A retrospective survey analysis. Adolescents. 2024;4(3):410-425.
Baser O, Rodchenko K, Zeng Y, Endrizal A. Mental health disparities in young adults with arrest history: A survey-based, cross-sectional analysis. Health Justice. 2024;12:1.
ISPOR EU 2024 Presentations
Barcelona, Spain: Nov 17-20, 2024
- A retrospective analysis of the impact of approved anti-obesity medications on the risk of cardiovascular disease in patients with obesity
- The impact of approved anti-obesity medications on the incidence of cardiovascular disease, healthcare resource use and costs among patients with obesity: A retrospective cohort study
- The impact of approved anti-obesity medications on the risk of obstructive sleep apnea in patients with obesity: A retrospective cohort study
- The impact of approved anti-obesity medications on the incidence of osteoarthritis, healthcare resource use and costs among patients with obesity: A retrospective cohort study (FINALIST AWARD)
- Anti-obesity medications and related osteoarthritis risk among patients with obesity
- The impact of approved anti-obesity medications on the incidence of obstructive sleep apnea, healthcare resource utilization and costs among patients with obesity: A retrospective cohort study (BEST RESEARCH POSTER AWARD)
Obesity Week 2024
San Antonio, TX: Nov 3-6, 2024
- Measuring the cardiovascular benefits of anti-obesity medications
- Head-to-head comparison of healthcare costs and utilization among patients with semaglutide vs tirzepatide use
- Likelihood of osteoarthritis among users of anti-obesity medications
- Likelihood of obstructive sleep apnea among patients with obesity and anti-obesity medication use
Psych Congress
Boston, MA: Oct 29 – Nov 2, 2024
- Open access to antipsychotics in state Medicaid programs: The effect on healthcare resource utilization and costs among patients with serious mental illness
- The effect of Medicaid reimbursement policies on serious mental illness outcomes
- The effect of the Medicaid institutions for mental disease exception on serious mental illness outcomes
American Public Health Association (APHA) Annual Meeting & Expo
Minneapolis, MN: Oct 27-30, 2024.
- The association between socioeconomic status and the likelihood and severity of RSV-attributable lower respiratory infections in infants
AMCP Nexus
Las Vegas, NV: Oct 14-17, 2024
- Effect of anti-obesity medications on cardiovascular events in the Veterans Affairs patient population
- Effect of weight loss medications on cardiovascular risk among active US military personnel (Bronze Ribbon Award)
- Cardiovascular benefits of weight loss medications: An analysis of Mounjaro and Wegovy in the US Medicare population
Infectious Diseases Society for Obstetrics and Gynecology (IDSOG) Annual Meeting
Portland, OR: Aug 1-3, 2024
- The association between socioeconomic status and maternal risk factors on the likelihood and severity of RSV-attributable lower respiratory infections from MarketScan data
ISPOR Annual Meeting
Atlanta, GA: May 5-8, 2024
- The effect of newly approved obesity medications on cardiovascular complications
- The effect of approved anti-obesity medications in patients with alcohol and substance use disorder
- The impact of approved anti-obesity medications on osteoarthritis risk in patients with obesity: A retrospective cohort study
- Predictive risk score for nonalcoholic steatohepatitis among patients in the Department of Defense population
- The cardiovascular effect of abiraterone and enzalutamide among Veterans Affairs’ metastatic castration-resistant prostate cancer patients (Podium presentation)
AMCP Annual Meeting
New Orleans, LA: April 15-18, 2024
- Socioeconomic status and postpartum depression among commercial health insurance enrollees (Bronze Poster Award)
- Open access for mental health medication: Impact on state Medicaid budgets
- The effect of Ozempic vs Wegovy vs Mounjaro on the incidence of alcohol and substance use disorder in obese patients (Bronze Poster Award)
- Impact of Ozempic vs Wegovy on osteoarthritis risk in obese patients: A retrospective cohort study (Bronze Poster Award)
- The effect of approved obesity medications on obesity’s cardiovascular related comorbidities
